文献速递MDS 与骨髓增殖性肿瘤

ZGJAK002长期随访后的疗效、安全性和生存结果:比较杰克替尼100 mg每日两次与200 mg每日一次治疗骨髓纤维化患者的2期研究

Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
PubMed 文献 · Am J Hematol · 2024-02-11

ZGJAK002是一项2期试验,评估杰克替尼100 mg每日两次(N=66)与200 mg每日一次(N=52)在未接受过JAK抑制剂治疗的中危或高危骨髓纤维化患者中的疗效与安全性,中位随访30.7个月。100 mg每日两次组最佳脾脏缓解率在数值上高于200 mg每日一次组(69.7% vs 46.2%),36个月生存率分别为78.2%和73.6%,两组耐受性总体良好。

要点

  • 100 mg每日两次组最佳脾脏缓解率69.7%,200 mg每日一次组46.2%,前者在数值上更高。
  • 36个月生存率100 mg每日两次组78.2%,200 mg每日一次组73.6%。
  • 药物相关严重不良事件发生率100 mg每日两次组24.2%,200 mg每日一次组9.6%,前者更高。

核心结论

  • 这些分析进一步支持杰克替尼100 mg每日两次和200 mg每日一次剂量治疗骨髓纤维化的长期持久疗效和可接受的安全性。

研究设计与样本

  • ZGJAK002是一项2期试验,旨在评估杰克替尼100 mg每日两次(N=66)和200 mg每日一次(N=52)在未接受过JAK抑制剂治疗的中危或高危骨髓纤维化患者中的疗效与安全性。
  • 本次报告长期数据,中位随访30.7个月。

主要发现

  • 数据截止时,100 mg每日两次组30.3%的患者和200 mg每日一次组28.8%的患者仍在继续治疗。
  • 100 mg每日两次组最佳脾脏缓解率在数值上高于200 mg每日一次组(69.7% vs 46.2%),100 mg每日两次组50.4%和200 mg每日一次组51.2%的患者维持脾脏缓解超过120周。
  • 36个月生存率100 mg每日两次组为78.2%,200 mg每日一次组为73.6%。
  • 常见≥3级药物不良反应在100 mg每日两次组和200 mg每日一次组分别为贫血(15.2% vs 21.2%)、血小板减少(15.2% vs 11.5%)和感染性肺炎(10.6% vs 1.9%)。
  • 两组不良事件发生率相似,但药物相关严重不良事件(24.2% vs 9.6%)和导致治疗中断的不良事件(15.2% vs 7.7%)在100 mg每日两次组更高;导致死亡的不良事件百分比相当,100 mg每日两次组6.1%,200 mg每日一次组5.8%。

临床怎么用

  • 原文结论为这些分析进一步支持杰克替尼100 mg每日两次和200 mg每日一次剂量治疗骨髓纤维化的长期持久疗效和可接受的安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Jaktinib, a novel JAK and ACVR1 inhibitor, has exhibited promising results in treating patients with myelofibrosis (MF). ZGJAK002 is a Phase 2 trial aimed to assess the efficacy and safety of jaktinib 100 mg BID (N = 66) and 200 mg QD (N = 52) in JAK inhibitor-naive patients with intermediate- or high-risk MF. We herein present the long-term data with a median follow-up of 30.7 months. At data cutoff, 30.3% of patients in 100 mg BID and 28.8% in 200 mg QD were still continuing their treatment. The 100 mg BID group displayed a numerically higher best spleen response compared with the 200 mg QD group (69.7% vs. 46.2%), with 50.4% from the BID and 51.2% from the QD group maintaining spleen responses over 120 weeks. The 36-month survival rates were 78.2% in BID and 73.6% in QD group. The tolerability of jaktinib remained well, and common grade ≥3 adverse drug reactions included anemia (15.2% vs. 21.2%), thrombocytopenia (15.2% vs. 11.5%), and infectious pneumonia (10.6% vs. 1.9%) in BID and QD groups, respectively. By comparing the two groups, the incidence of adverse events (AEs) were similar, except for drug-related serious AEs (24.2% vs. 9.6%) and AEs leading to treatment discontinuation (15.2% vs. 7.7%), which were higher in BID group. The percentages of AEs resulting in death were comparable, with 6.1% in BID and 5.8% in QD group. These analyses further support the long-term durable efficacy and acceptable safety of jaktinib at 100 mg BID and 200 mg QD doses for treating MF.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zhou H, Jiang Z, et al. Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis. Am J Hematol. 2024. PMID: 38343062. doi:10.1002/ajh.27245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。